Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
Optimizing Humira coverage is not just about reducing costs—it's about delivering effective, compassionate care while ...
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
Pharmacy benefits manager (PBM) RxPreferred has announced plans to offer the Humira biosimilar Yusimry through Mark Cuban Cost Plus Drugs – an online pharmacy launched by celebrity investor and ...
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.
or commonly used biological drugs like Humira, prescribed for rheumatoid arthritis. A 2024 study from Beth Israel Deaconess Medical Center found that about 15 million Americans use the new ...
SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...